Optimizing ADHD therapy with sustained-release methylphenidate.
Where this comes from
- Record sourced from PubMed, PMID 9105199.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rapid-release psychostimulants are commonly used to treat attention-deficit hyperactivity disorder (ADHD), but midday dosing requirements and poor compliance rates have prompted the development of sustained-release formulations. Sustained-release methylphenidate has been shown to have efficacy equal to that of the regular-release formulation and may be preferable when it is difficult or impossible to provide midday doses. Proper management of ADHD includes choosing the proper medication dosage, minimizing side effects of medications and periodically reevaluating the patient's progress.